Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Peanut allergy pill shows promise in early trial

NCT ID NCT05432388

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called remibrutinib in 76 adults with peanut allergy. Participants took one of three doses or a placebo daily for one month. The main goal was to see if the drug helped them eat more peanut protein without having an allergic reaction. Results showed some people on the drug could tolerate higher amounts of peanut protein compared to those on placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

76 people

The number who actually took part.

Started

Oct 2022

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Medical History of allergy to peanuts * Positive peanut IgE \>= 0.35 kUA/L * Positive Skin Prick test for peanut allergen during screening for study * Positive Oral Food Challenge to peanut during screening for study * Willingness to comply with study schedule and procedures and avoid other allergens during study period Exclusion Criteria: * History of severe or life-threatening hypersensitivity event leading to ICU admission or intubation within 60 days of screening * Uncontrolled asthma * Bleeding risk or coagulation disorder(s) * Use of anticoagulants or anti-platelets (aspirin or clopidogrel may be permitted) * History of splenectomy * Any significant disease that would put the safety of the patient at risk. This includes, but is not limited to: history of cancer, significant cardiac disease/history, hematology disorders, history of GI bleeding, active infectious process, liver disease, renal disease, immunologic disease (stable diabetes and thyroid disease may be permitted), alcohol or drug abuse, etc. Other protocol-defined inclusion/exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergy, peanut are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

food allergy Peanut Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergy, peanut

Contacts and locations

Locations

  • Allergy Associates of Utah

    Sandy City, Utah, 84093, United States

  • Allergy and Asthma Clin Res Inc

    Walnut Creek, California, 94598, United States

  • Allervie Clinical Research

    Birmingham, Alabama, 35209, United States

  • Arkansas Children's Hospital

    Little Rock, Arkansas, 72202, United States

  • Asthma and Allergy Associates P C

    Colorado Springs, Colorado, 80907, United States

  • Asthma and Allergy Center of Chicago S C

    River Forest, Illinois, 60305, United States

  • Bluegrass Allergy Research

    Lexington, Kentucky, 40509, United States

  • Bluegrass Allergy Research .

    Lexington, Kentucky, 40509, United States

  • CR Services Acquisition US

    Columbus, Ohio, 43213, United States

  • CR Services Acquisition US Main center

    Columbus, Ohio, 43213, United States

  • California Allergy and Asthma Medical Group

    Los Angeles, California, 90025, United States

  • CenExel HRI

    Berlin, New Jersey, 08009, United States

  • Childrens National Hospital

    Washington D.C., District of Columbia, 20010, United States

  • Colorado Allergy and Asthma Ctr PC

    Denver, Colorado, 80230, United States

  • Family Allergy and Asthma

    Louisville, Kentucky, 40217, United States

  • Institute for Asthma and Allergy PC

    Chevy Chase, Maryland, 20815, United States

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21287, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Midwest Allergy Sinus Asthma SC

    Normal, Illinois, 61761, United States

  • Seattle Allergy and Asthma Rsch

    Seattle, Washington, 98115, United States

  • Treasure Valley Medical Research

    Boise, Idaho, 83706, United States

  • University of Michigan Clinical Trials Office

    Ann Arbor, Michigan, 48109, United States

  • Vital Prospects Clinical Research Institute

    Tulsa, Oklahoma, 74136, United States

  • Western Sky Medical Research

    El Paso, Texas, 79924, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.